Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy - Top-Institutions - MDSpire

Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy

  • By

  • Xinwang Gong

  • Chang Zhou

  • Yutao Wu

  • May 1, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Icahn School of Medicine at Mount Sinai/The Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/The Mount Sinai Hospital

    New York, NY

    Key Differentiators

    • Cardiology

  • #2

    Brigham and Women’s Hospital (Harvard Medical School)
    Brigham and Women’s Hospital (Harvard Medical School)

    Boston, MA

    Key Differentiators

    • Cardiology

  • #3

    University Heart Center Freiburg
    University Heart Center Freiburg

    Freiburg, Germany

    Key Differentiators

    • Cardiology

  • #4

    German Heart Centre Munich
    German Heart Centre Munich

    Munich, Germany

    Key Differentiators

    • Cardiology

  • #5

    ISAResearch Center
    ISAResearch Center

    Location Unknown, Unknown

    Key Differentiators

    • Cardiology

Original Source(s)

Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy

  • by Xinwang Gong, Chang Zhou, Yutao Wu

  • May 1, 2026

Related Content

Construction and validation of a prediction model for in-stent restenosis following coronary stent implantation during dual antiplatelet therapy

Health economic simulation modeling of an AI-enabled clinical decision support system for coronary revascularization

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.